Hledat
Zobrazují se záznamy 1-4 z 4
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease
(2022)
Recently, we defined "CML-like" subtype of BCR::ABL1-positive acute lymphoblastic leukemia (ALL), resembling lymphoid blast crisis of chronic myeloid leukemia (CML). Here we retrospectively analyzed prognostic relevance ...
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on MRD-based protocol
(2023)
We compared minimal residual disease (MRD) levels evaluated by routinely used real-time quantitative PCR (qPCR) patient-specific assays and by next generation sequencing (NGS) approach in 780 immunoglobulin/T-cell receptor ...
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study
(2024)
Measurable residual disease (MRD) monitoring in childhood acute myeloid leukemia (AML) is used to assess response to treatment and for early detection of imminent relapse. In childhood AML, MRD is typically evaluated using ...
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
(2023)
We read with a great interest the paper focused on different minimal residual disease (MRD) approaches and its significance in Ph+ acute lymphoblastic leukemia (ALL) patients, authored by Short et al. from the MD Anderson ...